

CollabRx Partners with Life Technologies in Molecular Diagnostics

The Associated Press

SAN FRANCISCO--(BUSINESS WIRE)--Oct 3, 2012--CollabRx, Inc. (NASDAQ: CLRX) today announced a multi-year partnership agreement with Life Technologies Corporation for development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologies' global cancer diagnostics development and its laboratory developed test services business. The agreement represents a major step forward by CollabRx in providing laboratories and next-generation sequencing (NGS) companies with meaningful insights into cancer.

"Molecular analysis, including genetic sequencing, is increasingly becoming an important part of the clinical management of cancer patients," said James Karis, Co-CEO of CollabRx. "However, the sheer volume and complexity of genetic data that is being produced, particularly in the course of therapy development, is outpacing the ability of practicing physicians to stay current, and more importantly understand how to apply this genetic data in treating their patients." CollabRx, Inc., a data analytics company focused on genomics, bridges this knowledge gap using cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world's knowledge on molecular medicine with specific insights from the nation's top clinical experts.

Life Technologies will use CollabRx proprietary content and technology to pair the results of broad molecular profiling panels developed by Life Technologies with associated clinically relevant and dynamically updated knowledge on clinical trials, drugs, biologics and other information relevant for cancer treatment planning. This knowledge is supported by CollabRx's large and growing network of over 50 leading clinical practitioners in the United States. While CollabRx and its advisors do not provide specific treatment recommendations, this clinically relevant knowledge is a key part of the "context engine" for informing healthcare decision-making.

"It's critical to contextualize the results of complex cancer panels to make them useful for interpreting and treating physicians," said Ronnie Andrews, president of Medical Sciences at Life Technologies. "CollabRx has pioneered the development of a scalable platform and process to provide actionable, accessible, and credible knowledge at the point of care to aid physicians in developing a cancer treatment plan based on tumor molecular profiles. We are excited to include this key capability with our molecular diagnostic tests." "As the genomics revolution continues to unfold, successful cancer diagnostic companies will need cutting-edge technologies as well as deep, personalized analytics," said Thomas Mika, Co-CEO of CollabRx. "We are thrilled to be a part of Life Technologies' strategy to establish a leadership position in the clinical diagnostics market by providing ordering physicians with clinically relevant interpretation of test results, personalized for

CollabRx Partners with Life Technologies in Molecular Diagnostics

Published on Medical Design Technology (<http://www.mdtmag.com>)

each patient, as a seamless part of the reporting process via Web-based and mobile technologies." About CollabRx CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at <http://www.collabrx.com>.

CollabRx Safe Harbor Statement This press release includes forward-looking statements about CollabRx's anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx's plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Life Technologies' Safe Harbor Statement This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

CONTACT: CollabRx, Inc.

James M. Karis, Co-CEO, 415-248-5350 Thomas R. Mika, Co-CEO, 415-248-5350 or

CollabRx Partners with Life Technologies in Molecular Diagnostics

Published on Medical Design Technology (<http://www.mdtmag.com>)

Robert Ferri Partners, LLC Robert Ferri, 415-575-1589 (direct)
robert.ferri@robertferri.com KEYWORD: UNITED STATES NORTH AMERICA
CALIFORNIA INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE
HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS ONCOLOGY
PHARMACEUTICAL SOURCE: CollabRx, Inc. Copyright Business Wire 2012 PUB:
10/03/2012 04:03 PM/DISC: 10/03/2012 04:03 PM
<http://www.businesswire.com/news/home/20121003006512/>

Source URL (retrieved on 09/17/2014 - 11:47am):

http://www.mdtmag.com/news/2012/10/collabrx-partners-life-technologies-molecular-diagnostics?qt-most_popular=0&qt-recent_content=0